True Wealth Design’s Telomir Pharmaceuticals TELO Stock Holding History

True Wealth Design’s Portfolio TELO Stock Details TELO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3	Closed	-$4	–	2909
2025 Q2	$4	Buy	+3	New	+$7	﹤0.01%	2561

Other funds holding TELO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SEM

Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

True Wealth Design's TELO Position: Q3 2025 in Review

True Wealth Design sold out of Telomir Pharmaceuticals (TELO) in Q3 2025, closing a stake of 3 shares — an estimated $4 sold.

True Wealth Design first reported a position in TELO in Q2 2025 and held it in 1 quarter. The position peaked at $4 in Q2 2025. 32 funds tracked by Wall St. Rank hold TELO as of Q3 2025.

True Wealth Design reported no remaining Telomir Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
True Wealth Design sold 3 Telomir Pharmaceuticals shares in Q3 2025, an estimated $4.
True Wealth Design first reported a position in Telomir Pharmaceuticals in Q2 2025 and held it in 1 quarter.
True Wealth Design's Telomir Pharmaceuticals position peaked at $4 in Q2 2025.
32 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q3 2025.

Based on True Wealth Design's 13F filing for Q3 2025, filed 21 Oct 2025.